Patents by Inventor Stephan Roever

Stephan Roever has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spirocyclic compounds
    Patent number: 12227504
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: February 18, 2025
    Assignee: C4 Therepeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20230416251
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: January 24, 2023
    Publication date: December 28, 2023
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • Spirocyclic compounds
    Patent number: 11584748
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: February 21, 2023
    Assignee: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • Phenyl derivatives as cannabinoid receptor 2 agonists
    Patent number: 11339120
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: July 15, 2020
    Date of Patent: May 24, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Olivier Gavelle, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • PYRIDINE DERIVATIVES
    Publication number: 20220064178
    Abstract: The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: August 12, 2021
    Publication date: March 3, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • Pyridine derivatives
    Patent number: 11117903
    Abstract: The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: September 14, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS
    Publication number: 20210171441
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 15, 2020
    Publication date: June 10, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Olivier Gavelle, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • SPIROCYCLIC COMPOUNDS
    Publication number: 20210032245
    Abstract: The present invention provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.
    Type: Application
    Filed: October 16, 2020
    Publication date: February 4, 2021
    Applicant: C4 Therapeutics, Inc.
    Inventors: Christopher G. Nasveschuk, Fabian Dey, Annick Goergler, Bernd Kuhn, Roger Norcross, Stephan Roever, Philipp Schmid
  • PYRIDINE DERIVATIVES
    Publication number: 20200239490
    Abstract: The invention relates to compound of formula (I) wherein R1 to R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 20, 2019
    Publication date: July 30, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Didier Rombach
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20190248803
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 15, 2019
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Olivier GAVELLE, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Didier Rombach, Tanja Schulz-Gasch
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20180327396
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 24, 2018
    Publication date: November 15, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca Gobbi, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20180327360
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: July 20, 2018
    Publication date: November 15, 2018
    Applicants: Hoffmann-La Roche Inc., Eidgenossische Technische Hochschule Zurich
    Inventors: Luca Gobbi, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Roger Slavik
  • PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS
    Publication number: 20180290966
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: June 8, 2018
    Publication date: October 11, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Olivier GAVELLE, Uwe GRETHER, Matthias NETTEKOVEN, Stephan ROEVER, Mark ROGERS-EVANS, Didier ROMBACH
  • Pyrazol derivatives
    Patent number: 9694012
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 4, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Fabienne Ricklin, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • Triazolo[4,5-D]pyrimidine derivatives
    Patent number: 9593123
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: March 14, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Uwe Grether, Matthias Nettekoven, Mark Rogers-Evans, Stephan Roever, Sebastien Schmitt, Atsushi Kimbara
  • Pyrrolo[2,3-D]pyrimidine derivatives as CB2 receptor agonists
    Patent number: 9580435
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: February 28, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch
  • NOVEL PYRAZOL DERIVATIVES
    Publication number: 20170035769
    Abstract: The invention relates to a compound of formula (I) wherein A1 to A3 and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: October 24, 2016
    Publication date: February 9, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: UWE GRETHER, ATSUSHI KIMBARA, MATTHIAS NETTEKOVEN, FABIENNE RICKLIN, STEPHAN ROEVER, MARK ROGERS-EVANS, TANJA SCHULZ-GASCH
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160376262
    Abstract: The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca Gobbi, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans
  • NOVEL PYRIDINE DERIVATIVES
    Publication number: 20160376237
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Luca Gobbi, Uwe Grether, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Roger Slavik
  • Pyridine derivatives
    Patent number: 9522886
    Abstract: The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: December 20, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Beat Frei, Luca Gobbi, Uwe Grether, Atsushi Kimbara, Matthias Nettekoven, Stephan Roever, Mark Rogers-Evans, Tanja Schulz-Gasch